[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myelosuppression\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myelosuppression":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,44,70,92,119,140,161],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100592385","phase-2-trilaciclib-in-patients-receiving-sacituzumab-tirumotecan-for-egfr-mutated-advanced-non-small-cell-lung-cancer-nsclc-100592385",false,"NCT06992739","Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)","A Prospective, Single-arm Phase II Trial of Trilaciclib Administered Prior to Sacituzumab Tirumotecan in Patients With EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors（PROTECT-2）","PROTECT-2","Inclusion Criteria:\n\n1. Age range: 18-75 years old; No gender restrictions;\n2. ECOG PS score 0-1;\n3. Expected survival time ≥ 3 months;\n4. Patients with locally advanced or metastatic EGFR mutant non-small cell lung cancer diagnosed by histological or cytological examination, who have failed third-generation EGFR-TKI treatment and have experienced up to second-line EGFR-TKI treatment failure;\n\n   1. Patients who have only progressed with 1-2 generations of EGFR-TKI treatment need to undergo third-generation EGFR-TKI treatment;\n   2. If patients receive third-generation EGFR-TKI during neoadjuvant and\u002For postoperative adjuvant therapy and progress to metastatic or locally advanced disease more than 6 months after the last dose, they need to receive third-generation EGFR-TKI treatment again before they can participate in this study;\n   3. If patients receive third-generation EGFR-TKI during neoadjuvant and\u002For postoperative adjuvant therapy and progress to metastatic or locally advanced disease within 6 months after the last dose, they can directly participate in this study;\n   4. Imaging disease progression was recorded during or after the recent first-line treatment process.\n5. There must be at least one measurable lesion that meets the RECIST 1.1 criteria;\n6. The main organ functions well and meets the following standards:\n\n   Blood routine examination (without blood transfusion or correction with hematopoietic stimulating factor drugs within 14 days): hemoglobin (Hb) ≥ 90g\u002FL; Absolute neutrophil count (ANC) ≥ 1.5 × 109\u002FL; Platelet count (PLT) ≥ 80 × 109\u002FL; Biochemical examination: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN (≤ 5 × ULN for patients with liver metastasis); Serum total bilirubin (TBIL) ≤ 1.5 × ULN (Gilbert syndrome subjects, ≤ 3×ULN）； Serum creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance rate ≥ 60mL\u002Fmin; Coagulation function: activated partial thromboplastin time (APTT), international normalized ratio (INR), prothrombin time (PT) ≤ 1.5 × ULN;\n7. The subject must recover from all toxic reactions (except hair loss) of previous treatment to ≤ level 1 (evaluated based on CTCAE 5.0 criteria);\n8. Women: All women with potential fertility must have a negative serum pregnancy test result during the screening period, and must take reliable contraceptive measures from signing the informed consent form until 3 months after the last dose;\n9. Participants voluntarily participate in this study, understand and sign the informed consent form.\n\nExclusion Criteria:\n\n1. History of myeloid leukemia, myelodysplastic syndrome, or accompanying sickle cell disease;\n2. Symptomatic CNS metastases and\u002For leptomeningeal diseases that require immediate radiotherapy or steroid treatment;\n3. Have undergone surgery or radiation therapy within 4 weeks prior to the administration of the first dose of the study drug;\n4. Clinical symptoms or diseases of the heart that have not been well controlled, such as: (1) NYHA grade 2 or above heart failure; (2) Unstable angina pectoris; (3) Have experienced myocardial infarction within 6 months; (4) Patients with clinically significant supraventricular or ventricular arrhythmias that require treatment or intervention;\n5. History of interstitial lung disease, slow progressive dyspnea and dry cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary allergic pneumonia, or multiple allergic or peripheral arterial diseases (such as claudication, Leo Buerger's disease).\n6. Patients who have received hematopoietic stem cell or bone marrow transplantation in the past;\n7. Patients who need to receive radiation therapy at the same time;\n8. Those who are known to have a history of allergies to the components of this drug regimen;\n9. Pregnant or lactating women;\n10. The researcher believes that the patient is not suitable to participate in any other circumstances of this study.","ALL","18 Years","75 Years",{"count":21,"type":22},49,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This study is a prospective, single arm phase II clinical trial aimed at patients with advanced non-small cell lung cancer resistant to EGFR-TKI. The aim is to evaluate the efficacy and safety of trilaciclib in bone marrow protection before monotherapy with sacituzumab tirumotecan.\n\nPatients with advanced non-small cell lung cancer resistant to EGFR-TKI, after signing informed consent, will be screened for eligible subjects who meet the inclusion criteria. Prior to receiving treatment with sacituzumab tirumotecan, they will be treated with trilaciclib until disease progression or intolerable toxicity occurs.\n\nRecord the dynamic changes of whole blood cell count; Hematological toxicity, including febrile neutropenia and associated infections; Transfusion of blood products and supplementation of hematopoietic raw materials. Perform tumor imaging evaluation according to RECIST 1.1. Baseline imaging examination should be conducted within 21 days prior to the first administration, and tumor imaging evaluation shall be conducted every 6 weeks (± 7 days) from the first study drug administration, or the frequency of imaging evaluation may be increased when there are clinical indications. Subjects who terminate the study drug treatment due to intolerable toxicity or other non disease progression reasons continue to receive tumor evaluation follow-up until disease progression, withdrawal from the study, or death (whichever occurs earliest).\n\nAfter the screening period and one cycle of treatment, subjects may choose to undergo whole-body PET\u002FCT imaging for exploratory analysis.",[28,29,30],"NSCLC (Advanced Non-small Cell Lung Cancer)","EGFR","Myelosuppression","RECRUITING","2026-04-09",{"date":34,"type":35},"2026-04-14","ACTUAL",{"date":37,"type":35},"2025-12-08",{"date":39,"type":22},"2027-12",{"name":41,"class":42},"The First Affiliated Hospital of Xiamen University","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":68,"locationsCount":43},"100608744","phase-2-clinical-study-of-thiopegfilgrastim-for-preventing-bone-marrow-suppression-in-thoracic-tumor-chemoradiotherapy-100608744","NCT07205536","Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy","A Clinical Study on the Safety and Efficacy of Mecapegfilgrastim in Preventing Myelosuppression Induced by Concurrent Chemoradiotherapy for Thoracic Malignancies","ANC-IIT-004","Inclusion Criteria:\n\n* Aged 18-75 years at the time of giving informed consent， both sexes eligible\n* Histologically or cytologically confirmed thoracic tumor (esophageal or lung cancer)\n* Investigator judges the patient suitable for treatment with mecapegfilgrastim injection or leucogen tablets\n* Expected survival \\> 3 months\n* Signed informed consent; willing and able to comply with protocol-mandated visits\n* The patient is indicated for concurrent chemoradiotherapy and is currently\u002Freceiving or will receive a high-risk chemotherapy regimen for febrile neutropenia (FN risk ≥20%), or is currently\u002Freceiving or will receive an intermediate-risk chemotherapy regimen for FN (FN risk 10%\\~20%) with additional FN risk factors.\n\nExclusion Criteria:\n\n* Pregnant or lactating women\n* Known hypersensitivity to mecapegfilgrastim, pegylated or non-pegylated rhG-CSF, or any E. coli-derived product\n* Any severe comorbidity that, in the investigator's opinion, compromises patient safety or ability to complete the study\n* Any other condition that, in the investigator's judgment, could interfere with study conduct or interpretation of results",{"count":53,"type":22},30,[25],"This is a prospective observational study designed to observe and evaluate the safety and efficacy of mecapegfilgrastim in the treatment of moderate-to-severe myelosuppression associated with concurrent chemoradiotherapy. The project will provide more robust evidence-based medical support for the use of long-acting granulocyte-stimulating agents in patients undergoing concurrent chemoradiotherapy.",[30,57,58],"Thoracic Neoplasms","Chemoradiotherapy",[60,61],"Neutropenia","Febrile neutropenia","2025-12-10",{"date":64,"type":35},"2025-12-11",{"date":66,"type":35},"2025-08-01",{"date":39,"type":22},{"name":69,"class":42},"Affiliated Hospital of Nantong University",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":23,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":43},"100587557","phase-2-trilaciclib-in-combination-with-docetaxel-for-second-line-and-beyond-treatment-of-locally-advanced-or-metastatic-nsclc-100587557","NCT06929936","Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC","Phase II Clinical Trial of Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer","PROTECT-1","Inclusion Criteria:\n\nPatients must meet all of the following inclusion criteria to be included in this study:\n\n1. Age ≥ 18 years old, regardless of gender;\n2. Patients with stage IV NSCLC who have failed at least one line of standard treatment regimen:\n\n   A. Patients with negative driver genes must have received first line standard treatment (chemotherapy combined with immunotherapy).\n\n   B. Patients with positive driver genes must have received at least one line chemotherapy after standard targeted therapy has failed.\n\n   C. Definition of driver genes: EGFR (including 19del, L858R, S768I, L861Q, and\u002For G719X), BRAF V600E, NTRK, MET14 exon skipping mutation, RET, ROS1, etc.\n3. At least one measurable lesion that meets the RECIST 1.1 criteria exists;\n4. The laboratory test results meet the following criteria:\n\n   Hemoglobin ≥ 100 g\u002FL (female), 110g\u002FL (male) ,Neutrophil count ≥ 2×109\u002FL Platelet count ≥ 100×109\u002FL; Creatinine ≤15mg\u002FL or creatinine clearance rate (CrCl) ≥ 60mL\u002Fmin (Cockcroft Gault formula); Total bilirubin ≤ 1.5xupper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3×ULN or ≤ 5×ULN (for patients with liver metastases); Albumin ≥ 30 g\u002FL;\n5. ECOG PS score 0-2;\n6. Expected survival time ≥ 3 months;\n7. Women: All women with potential fertility must have a negative serum pregnancy test result during the screening period, and must take reliable contraceptive measures from signing the informed consent form until 3 months after the last dose;\n8. Understand and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Previously received treatment with docetaxel;\n2. Diagnosed with malignant diseases other than NSCLC within 5 years prior to the first administration (excluding curative basal cell carcinoma, squamous cell carcinoma, and\u002For excised carcinoma in situ);\n3. Uncontrolled ischemic heart disease or clinically significant congestive heart failure (NYHA class III or IV);\n4. Stroke or cardiovascular events within the first 6 months of enrollment;\n5. When screening, if the QTcF interval is greater than 480 milliseconds, for patients implanted with ventricular pacemakers, QTcF\\>500msec；\n6. Human immunodeficiency virus (HIV) infected individuals (HIV 1\u002F2 antibody positive), known syphilis infected individuals;\n7. Previously received hematopoietic stem cell or bone marrow transplantation;\n8. Allergies to research drugs or their components;\n9. The researchers believe that it is not suitable to participate in this study.",{"count":79,"type":22},33,[25],"This study is a prospective, single arm phase II study aimed at patients with locally advanced or metastatic non-small cell lung cancer undergoing second-line or beyond treatment. The aim is to evaluate the bone marrow protective effect of trilaciclib before docetaxel chemotherapy for locally advanced or metastatic NSCLC.",[83,30],"Non-Small Cell Lung Cancer","2025-06-06",{"date":86,"type":35},"2025-06-08",{"date":88,"type":35},"2025-05-09",{"date":90,"type":22},"2026-06",{"name":41,"class":42},{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":17,"minAge":99,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":23,"phases":103,"briefSummary":104,"conditions":105,"keywords":107,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":43},"100569840","phase-2-a-prospective-randomized-controlled-clinical-study-on-the-prevention-of-chemotherapy-related-myelosuppression-in-patients-with-ewings-sarcoma-using-trilaciclib-100569840","NCT06699472","A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib","A Prospective, Randomized, Controlled Clinical Study on the Prevention of VDC\u002FIE Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib","Inclusion Criteria:\n\n* Age ≥ 14 years old and ≤ 40 years old;\n* Histologically confirmed Ewing's sarcoma;\n* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 to 1;\n* Have not received any anti-tumor treatment other than surgery in the past;\n* Expected survival of more than 3 months;\n* Possess sufficient organ and bone marrow function, with laboratory test values meeting the following requirements within 7 days prior to enrollment (no blood components, cell growth factors, albumin, or other corrective treatment drugs are allowed within 14 days prior to obtaining laboratory tests), as follows Blood routine: Absolute neutrophil count (ANC) ≥ 1.5 × 109\u002FL, platelet count (PLT) ≥ 100 × 109\u002FL, hemoglobin (HGB) ≥ 100 g\u002FL (no transfusion or erythropoietin dependence within 14 days) Liver function: serum total bilirubin ≤ 1.25 times the upper limit of normal (ULN); ALT and AST ≤ 2.5 x ULN (≤ 5x ULN for patients with liver metastases); Serum albumin ≥ 30 g\u002FL; Alkaline phosphatase (ALP) ≤ 5 × ULN.\n\nRenal function: Serum creatinine (Cr) ≤ 1.25 × ULN, or creatinine clearance rate ≥ 60 mL\u002Fmin (using the standard Cockcroft Gault formula): Urine routine results show urinary protein\\\u003C2+; For patients whose baseline urine routine test shows urinary protein ≥ 2+, 24-hour urine collection should be performed with a 24-hour urine protein quantification of\\\u003C1g.\n\nCoagulation function: International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 times ULN; If the subject is receiving anticoagulant therapy, as long as the INR is within the intended range of use of the anticoagulant drug.\n\n* For female subjects of childbearing age, a urine or serum pregnancy test should be conducted 3 days before receiving the first study drug and the result should be negative;\n* The subjects and their sexual partners are required to use a medically approved contraceptive measure (such as intrauterine device, contraceptive pill, or condom) during the study treatment period and within 6 months after the end of the study treatment period.\n\nExclusion Criteria:\n\n* Previously received anti-tumor treatment other than surgery and radiation therapy for any malignant tumor;\n* Subjects who cannot accept or tolerate this chemotherapy regimen for various reasons;\n* Biopsy confirmed a patient with bone marrow infiltration;\n* The patient has undergone significant surgical procedures unrelated to Ewing's sarcoma within the 4 weeks prior to enrollment, or has not fully recovered from such surgical procedures;\n* Serious heart disease or discomfort, including but not limited to the following diseases:\n\nDiagnosed history of heart failure or systolic dysfunction (LVEF\\\u003C50%); High risk uncontrolled arrhythmias, such as atrial tachycardia, resting heart rate\\>100bpm, significant ventricular arrhythmias (such as ventricular tachycardia), or higher-level atrioventricular block (i.e. Mobitz II second or third degree atrioventricular block); Angina requiring treatment with anti angina drugs; Clinically significant heart valve disease; ECG shows transmural myocardial infarction; Poor control of hypertension (systolic blood pressure\\>180mmHg and\u002For diastolic blood pressure\\>100mmHg)\n\n* Individuals with a known history of allergies to the components of this medication regimen;\n* Breastfeeding female patients, female patients with fertility and positive baseline pregnancy test results, or reproductive age patients who are unwilling to take effective contraceptive measures during the entire trial period and within 7 months after the last study medication;\n* The researchers believe that the patient is not suitable to participate in any other circumstances of this study.","14 Years","40 Years",{"count":102,"type":22},22,[25],"This study is a prospective, open label, randomized controlled clinical trial aimed at patients with Ewing's sarcoma who have not received systematic anti-tumor treatment in the past. The aim is to evaluate the efficacy and safety of prophylactic use of Trilaciclib before VDC+IE chemotherapy.\n\nPatients with Ewing's sarcoma who have not received systemic anti-tumor therapy in the past will be screened for qualified subjects who meet the inclusion criteria after signing informed consent. Eligible patients will be randomly divided into an experimental group and a control group in a 1:1 ratio. The control group will receive alternating VDC+IE chemotherapy for 3 weeks, a total of 17 cycles, or until disease progression, intolerable adverse reactions, or withdrawal of informed consent occur. The experimental group received VDC+IE alternating chemotherapy combined with Trilaciclib, with 3 weeks as one course of treatment, for a total of 17 cycles or until disease progression, intolerable toxicity, withdrawal of informed consent, initiation of other anti-tumor treatments, death, or other situations specified in the protocol where treatment should be discontinued. Both the control group and the experimental group can receive supportive nursing treatment according to clinical needs.",[106,30],"Ewing Sarcoma",[106,30,108,109],"CDK4\u002F6 inhibitor","Chemotherapy","2024-11-19",{"date":112,"type":35},"2024-11-21",{"date":114,"type":35},"2024-10-31",{"date":116,"type":22},"2027-09-30",{"name":118,"class":42},"Fudan University",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":127,"phases":4,"briefSummary":123,"conditions":128,"keywords":129,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":43},"100565419","current-survey-on-chemotherapy-related-myelosuppression-and-clinical-management-in-chinese-county-level-tumor-patients-100565419","NCT06641934","Current Survey on Chemotherapy-Related Myelosuppression and Clinical Management in Chinese County-level Tumor Patients","Inclusion Criteria：\n\n* The confirmed malignant tumor is one of the non-small cell lung cancer\u002Fsmall cell lung cancer\u002Fbreast cancer\u002Fgastric cancer\u002Fesophageal cancer\u002Fcolorectal cancer\u002Fgynecological malignant tumor (ovarian cancer, cervical cancer, endometrial cancer).\n* Patients who need to receive chemotherapy in the past 3 months and should continue to receive chemotherapy in the future\n* The relevant diagnosis and treatment information involved in the survey is complete: only patients with at least 1-2 examination results after 1 week after chemotherapy can be included\n* Understand and sign the informed consent form\n* The chemotherapy regimen received for the most recent chemotherapy should be one of the following\n\n  1. Non-small cell lung cancer TP scheme NP scheme DP scheme EP scheme GP scheme AP scheme Docetaxel\u002Fpemetrexed monotherapy Gemcitabine monotherapy Tigio monotherapy ADCs Other monotherapy or combination regimens containing platinum or taxane drugs Drug regimens that combine the above chemotherapy regimens (e.g., immunosuppressants, targeted therapy drugs, etc.)\n  2. Small cell lung cancer with etoposide-containing combination regimens Platinum-containing combination regimens (except etoposide) Monotherapy or combination regimen containing topotecan, gemcitabine, paclitaxel Drug regimens that combine the above chemotherapy (e.g., immunosuppressants, targeted therapy drugs, etc.)\n  3. reast cancer ddEC sequential T regimen Anthracyclines and taxanes: TAC, TE, EC-T, ddEC-T, FEC-T regimens Combined taxane protocols: TP, AP, TC, Anthracycline combination regimen: EC, FEC Taxane monotherapy Yew combined with platinum Other platinum-containing regimens: NP, GP ADC drugs Microtubule inhibitors: NVB, taxanes (nab-paclitaxel, paclitaxel liposome, docetaxel), eutidrone, eribulin Microtubule inhibitors in combination with capecitabine Anthracycline monotherapy Drug regimens that combine the above chemotherapy (e.g., targeted therapy drugs, etc.)\n  4. Gastric cancer SOX protocol XELOX scheme FOLFOX protocol DCF scheme ADCs Other monotherapy or combination regimens containing platinum or taxanes or fluorouracil Drug regimens that combine the above chemotherapy (e.g., immunosuppressants, targeted therapy drugs, etc.)\n  5. Esophageal cancer taxane + platinum regimen CF protocol DCF scheme FOLFOX protocol XELOX scheme FLOT scheme FOLFIRI PROTOCOL ECF protocol ECX scheme EOF scheme EOX protocol Other monotherapy or combination regimens containing platinum or taxane or fluorouracil Drug regimens that combine the above chemotherapy (e.g., immunosuppressants, targeted therapy drugs, etc.)\n  6. COLORECTAL CANCER FOLFOXIRI FOLFOX FOLFIRI XELOX Other monotherapy or combination regimens containing platinum or fluorouracil or raltitrexed Drug regimens that combine the above chemotherapy (e.g., immunosuppressants, targeted therapy drugs, etc.)\n  7. Gynecologic malignancies:platinum + taxane or its combination regimen Monotherapy or combination chemotherapy containing docetaxel\u002Fgemcitabine\u002Ftopotecan\u002Firinotecan Regimens (except platinum + taxanes) Other monotherapy or combination chemotherapy regimens containing platinum, taxanes, or anthracyclines\n\nExclusion Criteria：\n\n* Patients with concurrent chemoradiotherapy,\n* Patients with sequential chemoradiotherapy, and the irradiation site of radiotherapy is flat bone, sternum, and pelvis;\n* Patients with active bleeding before or during treatment; If the patient has received targeted drugs such as CDK4\u002F6 inhibitors or chidaaniline in the front-line treatment, which have a great impact on the blood phase, the drug can be discontinued for at least half a month before it can be included\n* Patients who, in the opinion of other physicians, would cause non-chemotherapy-related myelosuppression",{"count":126,"type":22},1000,"OBSERVATIONAL",[30],[30],"NOT_YET_RECRUITING","2024-10-14",{"date":133,"type":35},"2024-10-16",{"date":135,"type":22},"2024-10-20",{"date":137,"type":22},"2025-12-20",{"name":139,"class":42},"The First Affiliated Hospital of Xinxiang Medical College",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":17,"minAge":100,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":23,"phases":149,"briefSummary":150,"conditions":151,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":43},"100553745","phase-2-trilaciclib-prevents-myelosuppression-with-chemoradiotherapy-100553745","NCT06490081","Trilaciclib Prevents Myelosuppression With Chemoradiotherapy","To Evaluate the Protective Effect of Trilaciclib on Myelosuppression in Patients With Limited-stage Small Cell Lung Cancer Associated With Concurrent Chemoradiotherapy and Discuss the Effect of Gut Microbiota Changes on Myelosuppression","Inclusion Criteria:\n\n1. The histopathology is limited-stage small cell lung cancer.\n2. ECOG score 0-2.\n3. Good organ function (no blood transfusions, no hematopoietic stimulating factors, no transfusions of albumin or blood products within 14 days prior to the examination).\n4. It is suitable for patients treated with Trilaciclib combined with etoposide plus cisplatin or carboplatin.\n5. Understand and can sign informed consent\n\nExclusion Criteria:\n\n1. Brain metastases with clinical symptoms require local radiotherapy or hormone therapy.\n2. Active infections require systemic treatment.\n3. Subjects with active, known or suspected autoimmune disease or history of autoimmune disease.\n4. Combined with other tumors.\n5. The current or previous presence of a clinically significant and medically unstable condition, which in the investigator's professional judgment may compromise subject safety, interfere with study evaluation or endpoint assessment, or otherwise impact the reliability of study results.",{"count":148,"type":22},40,[25],"To evaluate the protective effect of Trilaciclib on myelosuppression in patients with limited-stage small cell lung cancer associated with concurrent chemoradiotherapy and discuss the effect of gut microbiota changes on myelosuppression",[30],"2024-09-22",{"date":154,"type":35},"2024-09-24",{"date":156,"type":35},"2024-06-26",{"date":158,"type":22},"2026-06-30",{"name":160,"class":42},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":168,"enrollmentInfo":169,"targetDuration":4,"studyType":23,"phases":171,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":43},"100499210","phase-3-a-multi-center-randomized-double-blind-phase-iii-clinical-trial-of-leucogen-versus-placebo-on-leukocyte-and-platelet-whole-course-management-assisted-by-pfll-chemotherapy-in-the-treatment-of-stage-iv-recurrent-or-metastatic-npc-100499210","NCT05780294","A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC","A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-fluorouracil Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n1. ≥18 years old and ≤60 years old；\n2. Pathological diagnosis of stage IV, recurrent or distant metastatic nasopharyngeal carcinoma；\n3. Patients with stage IV, metastatic (including primary and secondary) or recurrent nasopharyngeal carcinoma who are not suitable for local treatment, local treatment mainly refers to measures related to anti-tumor therapy, including surgery, radiofrequency ablation, transhepatic artery chemoembolization (TACE), radiotherapy (excluding bone metastases, local moderate amount of radiation therapy for symptom relief without affecting hematological indicators)；\n4. Karnofsky functional status score should be at least 70 points (the decline of functional status score caused by tumor should be appropriately relaxed after the judgment of the researcher, and the minimum score should be no less than 50 points. );\n5. At least 1 measurable lesion according to RECIST1.1 assessment criteria, measurable lesion should not have received local treatment such as radiotherapy;\n6. Expected survival ≥3 months;\n7. The function of vital organs meets the following requirements (not allowed within 14 days before screening . May use any blood components, cell growth factors, leukoplast, platelets Drugs, anemia correction drugs) :\n\n   * Neutrophil absolute count (ANC) ≥1.5×109\u002FL\n   * Platelet ≥100×109\u002FL;\n   * Hemoglobin ≥8.0g\u002F dL (note: Hemoglobin ≥8.0g\u002F dL can be achieved through blood transfusion or other intervention);\n   * Serum albumin ≥2.8g\u002FdL;\n   * Bilirubin ≤ 1.5x ULN, ALT and AST≤ 1.5x ULN; ALT and AST≤ 5x ULN if liver metastasis was present;\n   * creatinine clearance ≥50mL\u002Fmin\n8. Women of non-surgical sterilization or reproductive age and sexually active men enrolled in the study are required to use a medically effective form of contraception (such as an intrauterine device \\[IUD\\], birth control pills or condoms) for the duration of the study treatment and for at least 3 months after the last use of Tamfu and for at least 6 months after the last use of chemotherapy; The serum or urine HCG test of female patients of reproductive age who were not undergoing surgical sterilization must be negative within 7 days prior to study enrollment. And must be non lactation period;\n9. Informed consent has been signed. -\n\nExclusion Criteria:\n\n1. Have a history of allergy to 5-FU, cisplatin and leucogen;\n2. Received elevated blood therapy 14 days prior to screening (including cytokines, leuk-lifting drugs, platelet-lifting drugs, anemia-correcting drugs, etc.)\n3. Major surgery other than nasopharyngeal cancer was diagnosed within 28 days prior to randomization or major surgery was expected during the study period;\n4. The subject has any active autoimmune disease or a history of autoimmune disease (e.g., but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism); Subjects with vitiligo or asthma in complete remission during childhood without any intervention as adults could be included; Subjects with asthma requiring medical intervention with bronchodilators were excluded);\n5. Subject is taking immunosuppressants, or systemic, or absorbable sites Hormone therapy to achieve immunosuppression (dose \\>10mg\u002F day prednisone or Other equally effective hormones) and continued to be used within 2 weeks prior to enrollment.\n6. The subject has previous or co-existing malignancies (except those that have been cured and survived for more than 5 years without cancer, such as basal cell carcinoma of the skin, carcinoma in situ of the cervix and papillary carcinoma of the thyroid);\n7. Patients with cardiac clinical symptoms or diseases that are not well controlled, such as: # HEART failure of NYHA grade 2 or above # unstable angina pectoris # myocardial infarction within 1 year # clinically significant ventricular arrhythmias or ventricular arrhythmias requiring treatment or intervention;\n8. Subjects have active infection or have unexplained fever \\>38.5 degrees during screening but before the first dose (the investigator judged that the subjects' fever due to tumor could be included in the study);\n9. Subjects with congenital or acquired immune deficiency (e.g. HIV infected), or active hepatitis (reference: HBsAg, anti-HBS, HBeAg, anti-HBC, anti-HBE, HBV DNA≥10#\u002Fml, liver cell transaminase, etc.); Hepatitis C reference: HCV antibodies and HCVRNA);\n10. The subject has a known history of psychotropic drug abuse, alcoholism or drug abuse;\n11. In the judgment of the researcher, the subject has other factors that may lead to the termination of the study, such as other serious diseases (including mental diseases) requiring combined treatment, serious abnormal laboratory examination, family or social factors, which may affect the safety of the subject, or the collection of test data and samples.\n12. Women who are pregnant or breastfeeding, or who refuse\u002Fcannot accept medically acceptable conditions. For women with potential pregnancy and sexually active men.\n\n    \\-","60 Years",{"count":170,"type":22},132,[172],"PHASE3","Toxic and side effects during and after chemoradiotherapy for nasopharyngeal carcinoma seriously affect patients' treatment compliance and long-term quality of life. Active and effective prediction, prevention and management of toxic and side effects is an important element to improve the prognosis of patients. Leucogen has the ability to promote the growth and maturation of granulocytes in the bone marrow and the proliferation of leukocytes, and is widely used in radiation therapy and chemotherapy-induced leukopenia in malignant carcinomas. In addition, leucogen may have potential anticancer synergistic effects. Therefore, based on the application prospect of leucogen in preventing myelosuppression during chemotherapy for solid tumors, the study was designed to investigate the efficacy and safety of leucogen versus placebo on leukocyte and platelet whole-course management assisted by platinum plus low-dose long-term continuous intravenous infused 5-fluorouracil chemotherapy in the treatment of stage IV, recurrent or metastatic nasopharyngeal carcinoma.",[175,176,109,30],"Nasopharyngeal Carcinoma","Leucogen","2023-03-10",{"date":179,"type":35},"2023-03-22",{"date":181,"type":22},"2023-04-01",{"date":183,"type":22},"2029-12-01",{"name":185,"class":42},"Sun Yat-sen University"]